Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Blinatumomab - Amgen

Drug Profile

Blinatumomab - Amgen

Alternative Names: AMG-103; Blincyto; MEDI-538; MT-103

Latest Information Update: 21 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Micromet Inc
  • Developer Amgen; Astellas Pharma; M. D. Anderson Cancer Center; Merck & Co; Micromet Inc; National Cancer Institute (USA); University of California, Davis
  • Class Antineoplastics; Bispecific antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - B-cell prolymphocytic leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma; B-cell lymphoma; Mantle-cell lymphoma; T-cell prolymphocytic leukaemia; Chronic lymphocytic leukaemia; Hairy cell leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Precursor B-cell lymphoblastic leukaemia-lymphoma
  • Phase II/III Non-Hodgkin's lymphoma
  • Phase II Diffuse large B cell lymphoma; Richter's syndrome
  • Clinical Phase Unknown Burkitt's lymphoma
  • Discontinued Chronic lymphocytic leukaemia

Most Recent Events

  • 31 Oct 2019 Blinatumomab licensed to BeiGene in China
  • 28 Oct 2019 Amgen completes a phase II trial in Diffuse large B cell lymphoma (Adjunctive treatment, Newly diagnosed) in Germany, Canada, France, Spain, United Kingdom, USA (IV) (NCT03023878)
  • 30 Sep 2019 Amgen terminates phase-II trial in Diffuse large B cell lymphoma (In adults, In the elderly, Second-line therapy or greater) in Switzerland, Italy, Greece, France, Belgium, Australia, USA (IV) (NCT03298412)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top